Trial Profile
Phase I Study of Combination of Sorafenib and LBH589 in Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 28 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record